• Researcher Profile

    Robert I. Haddad, MD

    Robert I. Haddad, MD

    Top Doctor

    Disease Center Leader, Head and Neck Oncology
    Institute Physician

    Associate Professor of Medicine, Harvard Medical School


    Head and Neck Cancer

    Office phone: 617-632-3090
    Fax: 617-632-4448

    Preferred contact method: office phone

    View Physician Profile

    Research Department

    Medical Oncology/Solid Tumor Oncology


    Head and neck oncology

    Area of Research

    Clinical Investigation of Head and Neck Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215


    Dr Haddad received his MD Degree from St. Joseph University French School of Medicine in Beirut. He completed his residency in internal medicine at St Luke's Roosevelt Medical Center in New York City, and completed a fellowship in hematology oncology at the University of Maryland Cancer Center in Baltimore.


    Clinical Investigation of Head and Neck Cancer

    As the clinical director of the Head and Neck Oncology Program, I care for patients with head and neck cancer and also supervise clinical trials involving these patients. They are typically treated in a multidisciplinary clinic in close collaboration with the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), the Department of Radiation Oncology at DFCI, dentistry, speech and swallow therapists, and oral surgery. I also conduct translational research in cooperation with Harvard School of Public Health, Harvard School of Dental Medicine, the Forsyth Institute, the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, and other disease centers. In addition, I am responsible for teaching fellows who rotate through the Head and Neck Cancer Program, as well as medical students, medical residents, and ear, nose, and throat residents through the DF/BWCC.

    My current clinical research activities involve the use of an intensive chemoradiotherapy regimen for patients with locally advanced head and neck cancer, with particular attention to radioprotection and cytoprotection. We have initiated a large randomized phase II study with chemoradiotherapy and subcutaneous amifostine. This very important study, conducted across multiple sites, opened and began accruing patients in 2005. We have also started a large phase III study, called the Paradigm Trial, that compares sequential chemoradiotherapy with concomitant chemoradiotherapy. This study will enroll more than 300 patients in different institutions around the country.

    In other research, we are working with the National Cancer Institute/Cancer Therapy Evaluation program to develop a phase II study examining the use of depsipeptide in head and neck cancer. We will also be looking at new molecules - including Erbitux (cetuximab), lapatinib, ZD6474, and others - for the treatment of head and neck cancer.

    Select Publications

    • Haddad R, Wirth L, Posner M. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther 2003;3:331-8.
    • Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-7.
    • Haddad R, Van Echo D. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol 2003;54:303-6.
    • Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol 2003;30(6 Supp 18):84-8.
    • Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 2004;10:4680-7.
    • Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10:944-6.
    • Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope 2004;114:1924-31.
    • Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol 2005;41:70-6.
    • Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF. Chemoradiation induced cell loss in human submandibular glands. Laryngoscope 2005;115:958-64.
    • Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM Jr, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:6976-81.
View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now